The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies.

Chiara Briani Andrea VisentinFrancesca CastellaniMario CacciavillaniLivio Trentin

Published in: Neurology(R) neuroimmunology & neuroinflammation (2022)

This study provides Class IV evidence that for a patient with relapsed anti-MAG antibody polyneuropathy, MYD88 wild-type, venetoclax plus rituximab is effective.

Keyphrases

wild type
chronic lymphocytic leukemia
diffuse large b cell lymphoma
hodgkin lymphoma
toll like receptor
acute lymphoblastic leukemia
acute myeloid leukemia
case report
immune response